Standard
SGLT-2 inhibitors versus GLP-1 receptor agonists and risk of mortality, chronic kidney disease and hospitalisation for heart failure in patients with type 2 diabetes. / Noergaard, C.; Torp-Pedersen, C.; Vestergaard, P.; Wong, N.; Gerds, T.; Starkopf, L.; Bonde, A.; Fosbol, E.; Kober, L.; Lee, C.
I:
European Heart Journal, Bind 40, Nr. Supplement 1, 194, 2019, s. 56.
Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › fagfællebedømt
Harvard
Noergaard, C, Torp-Pedersen, C, Vestergaard, P, Wong, N
, Gerds, T, Starkopf, L, Bonde, A, Fosbol, E
, Kober, L & Lee, C 2019, '
SGLT-2 inhibitors versus GLP-1 receptor agonists and risk of mortality, chronic kidney disease and hospitalisation for heart failure in patients with type 2 diabetes',
European Heart Journal, bind 40, nr. Supplement 1, 194, s. 56.
https://doi.org/10.1093/eurheartj/ehz747.0054APA
Noergaard, C., Torp-Pedersen, C., Vestergaard, P., Wong, N.
, Gerds, T., Starkopf, L., Bonde, A., Fosbol, E.
, Kober, L., & Lee, C. (2019).
SGLT-2 inhibitors versus GLP-1 receptor agonists and risk of mortality, chronic kidney disease and hospitalisation for heart failure in patients with type 2 diabetes.
European Heart Journal,
40(Supplement 1), 56. [194].
https://doi.org/10.1093/eurheartj/ehz747.0054Vancouver
Noergaard C, Torp-Pedersen C, Vestergaard P, Wong N
, Gerds T, Starkopf L o.a.
SGLT-2 inhibitors versus GLP-1 receptor agonists and risk of mortality, chronic kidney disease and hospitalisation for heart failure in patients with type 2 diabetes.
European Heart Journal. 2019;40(Supplement 1):56. 194.
https://doi.org/10.1093/eurheartj/ehz747.0054Author
Noergaard, C. ; Torp-Pedersen, C. ; Vestergaard, P. ; Wong, N. ; Gerds, T. ; Starkopf, L. ; Bonde, A. ; Fosbol, E. ; Kober, L. ; Lee, C. / SGLT-2 inhibitors versus GLP-1 receptor agonists and risk of mortality, chronic kidney disease and hospitalisation for heart failure in patients with type 2 diabetes. I: European Heart Journal. 2019 ; Bind 40, Nr. Supplement 1. s. 56.
Bibtex
@article{85fc3246d37b4753bb024ac2f6bf5285,
title = "SGLT-2 inhibitors versus GLP-1 receptor agonists and risk of mortality, chronic kidney disease and hospitalisation for heart failure in patients with type 2 diabetes",
author = "C. Noergaard and C. Torp-Pedersen and P. Vestergaard and N. Wong and T. Gerds and L. Starkopf and A. Bonde and E. Fosbol and L. Kober and C. Lee",
year = "2019",
doi = "10.1093/eurheartj/ehz747.0054",
language = "English",
volume = "40",
pages = "56",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "Supplement 1",
}
RIS
TY - ABST
T1 - SGLT-2 inhibitors versus GLP-1 receptor agonists and risk of mortality, chronic kidney disease and hospitalisation for heart failure in patients with type 2 diabetes
AU - Noergaard, C.
AU - Torp-Pedersen, C.
AU - Vestergaard, P.
AU - Wong, N.
AU - Gerds, T.
AU - Starkopf, L.
AU - Bonde, A.
AU - Fosbol, E.
AU - Kober, L.
AU - Lee, C.
PY - 2019
Y1 - 2019
U2 - 10.1093/eurheartj/ehz747.0054
DO - 10.1093/eurheartj/ehz747.0054
M3 - Conference abstract in journal
VL - 40
SP - 56
JO - European Heart Journal
JF - European Heart Journal
SN - 0195-668X
IS - Supplement 1
M1 - 194
ER -
